Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-03-15
1997-12-02
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241851, 4241881, 4241931, 4241941, 42419611, 530317, 530323, 530403, A61K 3921, A61K 39385
Patent
active
056933258
ABSTRACT:
There are disclosed peptide vaccines and methods related thereto for generating a protective immune response in warm-blooded animals. The peptide vaccines comprise a conformationally constrained reverse-turn mimetic, a T cell stimulatory peptide, and a cleavable linker covalently joining the conformationally constrained reverse-turn mimetic and the T cell stimulatory peptide. The conformationally constrained reverse-turn mimetic mimics the three-dimensional structure of an antigenic determinant of a native pathogenic protein and is capable of binding to a B cell. Upon binding to a B cell, the peptide vaccine is internalized, and the T cell stimulatory peptide is released from the conformationally constrained reverse-turn mimetic by cleavage of the cleavable linker. The T cell stimulatory peptide is then expressed on the surface of the B cell in association with class I or II MHC molecules, thus inducing T cell activity and generating a protective immune response.
REFERENCES:
patent: 5334702 (1994-08-01), Greene et al.
Sato et al (1993) Bioorg. Med. Chem. Lett, 3(6):1277-1282.
Chen et al., "Design and Synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes," Proc. Natl. Acad. Sci. USA 89:5872-5876, 1992.
Johnson et al., "Hypothesis: Conformational rearrangements required of the V3 loop of HIV-1 gp120 for proteolytic cleavage and infection," FEBS Letters 337:4-8, 1994.
Ahlers et al., "Construction of an HIV-1 Peptide Vaccine Containing a Multideterminant Helper Peptide Linked to a V3 Loop Peptide 18 Inducing Strong Neutralizing Antibody Responses in Mice of Multiple MHC Haplotypes after Two Immunizations," J. Immunol. 150(12):5647-5665, 1993.
Tolman et al., "Cyclic V3-loop-related HIV-1 conjugate vaccines," International Journal of Peptide & Protein Research 41:455-466, 1993.
Warren et al., "Examination of Sera from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals for Antibodies Reactive with Peptides Corresponding to the Principal Neutralizing Determinant of HIV-1 gp120 and for In Vitro Neutralizing Activity," J. Virol. 66(9):5210-5215, 1992.
Lasky et al., "Delineation of a Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical for Interaction with the CD4 Receptor," Cell 50:975-985, 1987.
Palker et al., "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen Comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes", J. Immunol. 142(10):3612-3619, 1989.
Leonetti et al., "Immunization with a Peptide Having Both T Cell and Conformationally Restricted B Cell Epitopes Elicits Neutralizing Antisera Against a Snake Neurotoxin", J. Immunol. 145(12):4214-4221, 1990.
Wyatt et al., "Relationship of the Human Immunodeficiency Virus Type 1 gp120 Third Variable Loop to a Component of the CD4 Binding Site in the Fourth Conserved Region", J. Immunol. 66(12):6997-7004, 1992.
Cease et al., "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide", Proc. Natl. Acad. Sci. USA 84:4249-4253, 1987.
Sastry et al., "Rapid in Vivo Induction of HIV-Specific CD8+ Cytotoxic T Lymphocytes by a 15-Amino Acid Unmodified Free Peptide from the Immunodominant V3-Loop of GP 120", Virology 188:502-509, 1992.
Henrickson et al., "Neutralizing epitopes of human parainfluenza virus type 3 are conformational and cannot be imitated by synthetic peptides", Vaccine 9:243-249, 1991.
Muller et al., "Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin", Vaccine 8:308-314, 1990.
Knossow et al., "Three-dimensional structure of an antigenic mutant of the influenza virus haemagglutinin", Nature 311:678-680, 1984.
Van Noort and van der Drift, "The Selectivity of Cathepsin D Suggests an Involvement of the Enzyme in the Generation of T-cell Epitopes", The Journal of Biological Chemistry 264(24): 14159-14164, 1989.
Zaloom and Roberts, "Preparation of Azido Derivatives from Amino Acids and Peptides by Diazo Transfer", J. Org. Chem. 46:5173-5176, 1981.
Milich, "Synthetic T and B Cell Recognition Sites: Implications for Vaccine Development", Advances in Immunology 45:204-209 and 240-251, 1989.
Arnon and Regenmortel, "Structural basis of antigenic specificity and design of new vaccines", The FASEB Journal 6:3265-3274, 1992.
Berzofsky, "Mechanisms of T Cell Recognition with Application to Vaccine Design," Molecular Immunology 28(3):217-223, 1991.
Achutamurthy Ponnathapura
Molecumetics Ltd.
LandOfFree
Peptide vaccines and methods relating thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide vaccines and methods relating thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide vaccines and methods relating thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-799077